Costs of nosocomial pneumonia caused by meticillin-resistant Staphylococcus aureus
| Autor: | Iris F. Chaberny, Frank J. Schwab, Ella Ott, C. Reichardt, Franz-Christoph Bange, Karolin Graf, M. Eckstein |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Microbiology (medical)
Male Methicillin-Resistant Staphylococcus aureus medicine.medical_specialty Meticillin medicine.disease_cause Intensive care Internal medicine Epidemiology Pneumonia Staphylococcal medicine Humans Intensive care medicine Antibacterial agent Aged Cross Infection business.industry Respiratory disease Bacterial pneumonia General Medicine Health Care Costs biochemical phenomena metabolism and nutrition Middle Aged bacterial infections and mycoses medicine.disease respiratory tract diseases Pneumonia Infectious Diseases Staphylococcus aureus Case-Control Studies Female business medicine.drug |
| Zdroj: | The Journal of hospital infection. 76(4) |
| ISSN: | 1532-2939 |
| Popis: | summary Nosocomial infections with meticillin-resistant Staphylococcus aureus (MRSA) lead to increased health and economic costs. The purpose of this study was to determine costs for nosocomial MRSA pneumonia compared with meticillin-susceptible S. aureus (MSSA) pneumonia. A caseecontrol study was conducted with patients who acquired nosocomial pneumonia with either MRSA or MSSA between January 2005 and December 2007. Patients were matched for age, severity of underlying disease, stay on intensive care units and nonintensive care units, admission and discharge within the same year, and in-hospital stay at least as long as that of cases before MRSA pneumonia. Our analysis includes 82 patients (41 cases, 41 controls). The overall costs for patients with nosocomial MRSA pneumonia were significantly higher than for patients with MSSA pneumonia (V60,684 vs V38,731; P ¼0.01). The attributable costs for MRSA pneumonia per patient were V17,282 (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect